Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 105

Sort by

Sort Order Select

Journal Articles

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Madan Jagasia, Miguel-Angel Perales, Mark A. Schroeder, Haris Ali, Nirav N. Shah, Yi-Bin Chen, Salman Fazal, Fitzroy W. Dawkins, Michael C. Arbushites, Chuan Tian, Laura Connelly-Smith, Michael D. Howell, H. Jean Khoury

Blood (2020) 135 (20): 1739–1749.

https://doi.org/10.1182/blood.2020004823

Published: 2020

Includes: Supplemental data

Journal Articles

Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

Madan Jagasia, MD MS, Miguel-Angel Perales, MD, Mark A Schroeder, MD, Haris Ali, MD, Nirav N Shah, MD, Yi-Bin Chen, MD, Michael C. Arbushites, Fitzroy Dawkins, MD, Chuan Tian, PhD, Hanna Jean Khoury, MD FACP

Blood (2018) 132 (Supplement 1): 601.

https://doi.org/10.1182/blood-2018-99-116342

Published: 2018

Journal Articles

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Blood (2018) 132 (4): 393–404.

https://doi.org/10.1182/blood-2016-09-739086

Published: 2018

Includes: Supplemental data

Journal Articles

Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome‒Positive Chronic Myeloid Leukemia

Vamsi Kota, MD, Tim H. Brümmendorf, MD, Carlo Gambacorti-Passerini, MD, Jorge E. Cortes, MD, Jeffrey H. Lipton, MD PhD, Hagop M. Kantarjian, MD, Dong-Wook Kim, MD PhD, Fiona An, MD, Eric Leip, PhD, Rocco J. Crescenzo, DO, FACOI, Mabel Woloj, PhD, Mark Shapiro, MD PhD, H. Jean Khoury, MD FACP

Blood (2016) 128 (22): 1921.

https://doi.org/10.1182/blood.V128.22.1921.1921

Published: 2016

Journal Articles

Consolidation Chemotherapy Is Not Beneficial for Adult Acute Lymphoblastic Leukemia Patients with Available Donor Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation in First Complete Remission: A CIBMTR Study

Nelli Bejanyan, MD, Aleksandr Lazaryan, MD PhD MPH, Mei-Jie Zhang, PhD, Hai-Lin Wang, MPH, Marcos de Lima, MD, Brenda M. Sandmaier, MD, Mary M. Horowitz, MD MS, H. Jean Khoury, MD, Daniel J. Weisdorf, MD

Blood (2016) 128 (22): 684.

https://doi.org/10.1182/blood.V128.22.684.684

Published: 2016

Journal Articles

Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia

Blood (2016) 128 (22): 679.

https://doi.org/10.1182/blood.V128.22.679.679

Published: 2016

Journal Articles

A Phase I Trial of Janus Kinase (JAK) Inhibition with INCB039110 in Acute Graft-Versus-Host Disease (aGVHD)

Mark A. Schroeder, MD, H. Jean Khoury, MD FACP, Madan Jagasia, MD MS, Haris Ali, MD, Gary J. Schiller, MD, Michael Arbushites, Patricia Delaite, Ying Yan, Kathleen Rhein, Miguel-Angel Perales, MD, Yi-Bin Chen, MD, John F DiPersio, MD PhD

Blood (2016) 128 (22): 390.

https://doi.org/10.1182/blood.V128.22.390.390

Published: 2016

Journal Articles

A Prospective Multi-Center Trial Shows Reduction of Early Deaths (ED) and Improved Survival in Elderly Acute Promyelocytic Leukemia (APL) Patients (>60 years). Results of Using a Simplified Treatment Algorithm and Expert Support in Georgia, South Carolina and Neighboring States

Blood (2016) 128 (22): 1622.

https://doi.org/10.1182/blood.V128.22.1622.1622

Published: 2016

Journal Articles

A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States

Blood (2016) 128 (22): 2793.

https://doi.org/10.1182/blood.V128.22.2793.2793

Published: 2016

Journal Articles

Outcomes of Chronic Phase Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitors Dose-Reductions

Jee Hyun Kong, MD, Hanna Jean Khoury, MD, Elliott F. Winton, MD, Leonard T. Heffner, MD, Manila Gaddh, MD, Martha Arellano, MD, Fuad El-Rassi, MD, Audrey S Kim, RN, Anand Jillella, MD, Imre Bodó, MDPhD, Vamsi Kota, MD

Blood (2016) 128 (22): 3093.

https://doi.org/10.1182/blood.V128.22.3093.3093

Published: 2016

Journal Articles

Acute Chest Syndrome Rate at the Emory University Georgia Comprehensive Sickle Cell Center at Grady Health System

Fuad El Rassi, MD, Eldrida Randall, MS, Sidney F. Stein, MD, H. Jean Khoury, MD, James R. Eckman, MD, Morgan L. McLemore, MD

Blood (2015) 126 (23): 3420.

https://doi.org/10.1182/blood.V126.23.3420.3420

Published: 2015

Journal Articles

Poor Outcomes with Hyper CVAD Induction for T-Cell Lymphoblastic Leukemia/Lymphoma

Vamsi K Kota, MD, Amanda Redden Hathaway, MD, Bijal D. Shah, MD, Deniz Peker, MD, Ling Zhang, MD, David L. Jaye, MD, Martha Arellano, MD, H Jean Khoury, Anand P Jillella, MD, Elliott F. Winton, MD, Leonard T Heffner, Jr., MD, Uma Borate, MD

Blood (2015) 126 (23): 3762.

https://doi.org/10.1182/blood.V126.23.3762.3762

Published: 2015

Journal Articles

A Phase I Study of IGN523, a Novel Anti-CD98 Monoclonal Antibody in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Dale Bixby, MD PhD, Matthew J. Wieduwilt, MD PhD, Luke Paul Akard, MD, H. Jean Khoury, MD, Pamela S. Becker, MD PhD, Edward H. Van Der Horst, PhD, William Ho, MD PhD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 3809.

https://doi.org/10.1182/blood.V126.23.3809.3809

Published: 2015

Journal Articles

Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study

Blood (2015) 126 (23): 5142.

https://doi.org/10.1182/blood.V126.23.5142.5142

Published: 2015

Journal Articles

Outcomes of Allogeneic Transplantation in Patients Aged ≤ 60 Years with Acute Myeloid Leukemia in Second Complete Remission: A CIBMTR ® Cohort Analysis

Fotios V. Michelis, MDPhD, Vikas Gupta, MD FRCP, FRCPath, Mei-Jie Zhang, PhD, Hai-Lin Wang, MPH, Marcos de Lima, MD, Hanna Jean Khoury, MD, Brenda M Sandmaier, MD, Wael Saber, MD MS

Blood (2015) 126 (23): 2009.

https://doi.org/10.1182/blood.V126.23.2009.2009

Published: 2015

Journal Articles

Comparison of Post-Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes after Matched Related Donor Versus Matched Unrelated Donor HCT in Adults with Acute Lymphoblastic Leukemia

Eric Segal, BS, Michael Martens, MS, Hai-Lin Wang, MPH, Ruta Brazauskas, PhD, Daniel Weisdorf, MD, Brenda M. Sandmaier, MD, Marcos J de Lima, MD, H. Jean Khoury, MD, Wael Saber, MD MS

Blood (2015) 126 (23): 2017.

https://doi.org/10.1182/blood.V126.23.2017.2017

Published: 2015

Journal Articles

Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD)

H. Jean Khoury, Vamsi Kota, M.B;B.S, Martha Arellano, MD, Stephanie L Bauer, ANP, Anand P Jillella, MD, Amelia Langston, MD, Zaid Al-Kadhimi, MD, Zachariah DeFilipp, MD, Audrey S Kim, RN, Elliott F. Winton, MD, John F Dipersio, MD PhD

Blood (2015) 126 (23): 1938.

https://doi.org/10.1182/blood.V126.23.1938.1938

Published: 2015

Journal Articles

Outcomes of Grades II-IV Acute Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation: How Much Progress Was Achieved?

Hanna Jean Khoury, MD, Tao Wang, PhD, Mukta Arora, MD, Michael Hemmer, MS, Stephen R. Spellman, MBS, Corey S Cutler, MD MPH, Daniel R. Couriel, MD, Amin M. Alousi, MD, Joseph A. Joseph, MD

Blood (2015) 126 (23): 3132.

https://doi.org/10.1182/blood.V126.23.3132.3132

Published: 2015

Journal Articles

Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Who Switch to Imatinib Following Optimal Response to Second Generation Tyrosine Kinase Inhibitors

Vamsi K Kota, MD, Elliott F. Winton, MD, Martha Arellano, MD, Anand Jillella, Morgan L. McLemore, MD, Fuad El Rassi, MD, H Jean Khoury

Blood (2015) 126 (23): 1592.

https://doi.org/10.1182/blood.V126.23.1592.1592

Published: 2015

Journal Articles

Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Single US Center Experience

H Jean Khoury, Leonard T Heffner, Jr., MD, Martha Arellano, MD, Anand P Jillella, MD, Vamsi K Kota, MD, Elliott F. Winton, MD

Blood (2015) 126 (23): 4045.

https://doi.org/10.1182/blood.V126.23.4045.4045

Published: 2015

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome‒Positive Chronic Myeloid Leukemia

Consolidation Chemotherapy Is Not Beneficial for Adult Acute Lymphoblastic Leukemia Patients with Available Donor Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation in First Complete Remission: A CIBMTR Study

Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia

A Phase I Trial of Janus Kinase (JAK) Inhibition with INCB039110 in Acute Graft-Versus-Host Disease (aGVHD)

A Prospective Multi-Center Trial Shows Reduction of Early Deaths (ED) and Improved Survival in Elderly Acute Promyelocytic Leukemia (APL) Patients (>60 years). Results of Using a Simplified Treatment Algorithm and Expert Support in Georgia, South Carolina and Neighboring States

A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States

Outcomes of Chronic Phase Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitors Dose-Reductions

Acute Chest Syndrome Rate at the Emory University Georgia Comprehensive Sickle Cell Center at Grady Health System

Poor Outcomes with Hyper CVAD Induction for T-Cell Lymphoblastic Leukemia/Lymphoma

A Phase I Study of IGN523, a Novel Anti-CD98 Monoclonal Antibody in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study

Outcomes of Allogeneic Transplantation in Patients Aged ≤ 60 Years with Acute Myeloid Leukemia in Second Complete Remission: A CIBMTR ® Cohort Analysis

Comparison of Post-Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes after Matched Related Donor Versus Matched Unrelated Donor HCT in Adults with Acute Lymphoblastic Leukemia

Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD)

Outcomes of Grades II-IV Acute Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation: How Much Progress Was Achieved?

Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Who Switch to Imatinib Following Optimal Response to Second Generation Tyrosine Kinase Inhibitors

Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Single US Center Experience

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only